- Resibufogenin
-
- $48.00
-
2026-06-02
- CAS:465-39-4
- Purity: 99.17%
- Supply Ability: 10g
- Resibufogenin
-
- $1.00
-
2019-07-06
- CAS:465-39-4
- Min. Order: 1kg
- Purity: 95%-99%
- Supply Ability: 100kg
|
| | Resibufogenin Basic information |
| Product Name: | Resibufogenin | | Synonyms: | bufogenina;rbg;RESIBUFOGENIN;RESIBUFOGENIN95%,97%;(3BETA,5BETA,15BETA)-14,15EPOXY-3-HYDROXY-5-BUFA-20,22-DIENOLIDE;20,22,5BETA-BUFADIENOLID-14BETA,15BETA-EPOXY-3BETA-OL;BUFOGENIN;5-beta-Bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta-hydroxy- | | CAS: | 465-39-4 | | MF: | C24H32O4 | | MW: | 384.51 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Steroids | | Mol File: | 465-39-4.mol |  |
| | Resibufogenin Chemical Properties |
| Melting point | 113-140°/155-168° | | alpha | D22 -7.1° (c = 1.259 in chloroform); D16 -5.4° (c = 2.030 in chloroform) | | Boiling point | 431.17°C (rough estimate) | | density | 1.0474 (rough estimate) | | refractive index | 1.4860 (estimate) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMF: 25 mg/mL; DMF:PBS(pH 7.2)(1:1): 0.5 mg/mL; DMSO: 20 mg/mL; Ethanol: 5 mg/mL | | form | White to off-white solid. | | pka | 15.14±0.70(Predicted) | | color | White to off-white | | Stability: | Moisture Sensitive | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | InChIKey | ATLJNLYIJOCWJE-CWMZOUAVSA-N | | SMILES | C[C@@]12[C@@]3(O[C@@H]3C[C@@H]2C4=COC(C=C4)=O)[C@]5([H])CC[C@]6([H])C[C@@H](O)CC[C@]6(C)[C@@]5([H])CC1 |
| Safety Statements | 24/25 | | RIDADR | 3172 | | WGK Germany | WGK 3 | | HazardClass | 6.1(a) | | PackingGroup | II | | HS Code | 29322090 | | Storage Class | 6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | | Hazard Classifications | Acute Tox. 2 Dermal
Acute Tox. 2 Inhalation
Acute Tox. 2 Oral | | Toxicity | LD50 oral in mouse: 59800mg/kg |
| | Resibufogenin Usage And Synthesis |
| Description | As one of the active components of Bufonis bufa, Resibufogenin is speculated that Etobufaxin can inhibit the proliferation of tumor cells by inducing apoptosis of osteosarcoma cells. | | Uses | Resibufogenin is used for content determination/identification/pharmacological experiments, etc. | | Definition | ChEBI: Bufogenin is a steroid lactone of Chan su (toad venom), a Chinese medicine obtained from the skin venom gland of toads. A specific Na/K-ATPase protein inhibitor, it is used as a cardiotonic and central nervous system (CNS) respiratory agent, an analgesic and anesthetic, and as a remedy for ulcers. It has a role as an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a steroid lactone and an epoxy steroid. It is functionally related to a bufanolide. | | Biological Activity | Resibufogenin (Bufogenin, Recibufogenin) is the anticancer component of huachansu cinobufogenin, which triggers necrosis by up-regulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating Ser358 of mixed lineage kinase domain-like protein. It exerts cytotoxic effects by inducing the accumulation of reactive oxygen species (ROS). Resibufogenin induces apoptosis and caspase-3 and caspase-8 activity. Also it increases Bax/Bcl-2 expression and inhibits protein expression of cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin. | | Pharmacokinetics | The main pharmacological action of acetobufaxin is anti-tumor. The cinobufavidin injection was separated by modern chromatographic techniques, and the exobufaxin compounds were obtained. The main monomers of exobufaxin were analyzed and identified by HPLC-DAD-FT-ICR-MS. The anti-tumor activity of exobufaxin was screened in vitro, and the pancreatic cancer tumor-bearing nude mouse model was established in vivo to evaluate the efficacy of exobufaxin. | | target | | Target | Value | RIP3
() | MLK
() | ROS
() | Caspase-3
() | Caspase-8
() | | |
|
| | Resibufogenin Preparation Products And Raw materials |
|